Your browser doesn't support javascript.
loading
On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II.
Sato, Y; Yoshida, P; Yamamoto, T; So, S; Tanizawa, K.
Affiliation
  • Sato Y; JCR Pharmaceuticals, Hyogo, Japan. Electronic address: sato-yuji@jp.jcrpharm.com.
  • Yoshida P; JCR Pharmaceuticals, Hyogo, Japan.
  • Yamamoto T; JCR Pharmaceuticals, Hyogo, Japan.
  • So S; JCR Pharmaceuticals, Hyogo, Japan.
  • Tanizawa K; JCR Pharmaceuticals, Hyogo, Japan.
Mol Genet Metab ; 141(3): 108143, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38277987
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis II Limits: Humans Language: En Journal: Mol Genet Metab Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis II Limits: Humans Language: En Journal: Mol Genet Metab Year: 2024 Document type: Article